Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going.

Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results impressed Wall Street in head and neck ...

Qureator has been testing BAL0891 in combination with Keytruda, a PD-1 inhibitor used in cancer immunotherapy, in organoid models of triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), ...

Spending on cancer drugs is expected to reach $441B globally in 2029 despite a slowdown later in the decade as key oncology ...

Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment.

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair ...

COPENHAGEN, Denmark I May 22, 2025 I Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ ...